patients receiving vaccine 44.2 months received placebo went average 30.6 months relapse patient remission decade vaccine called biovaxid undergoing phase iii clinical trials sponsored biovest international inc. personalized cancer vaccines research pipeline including melanoma vaccine developed massachusetts general hospital mgh bladder cancer vaccine despite successes tailored immunological attacks follicular lymphoma not lymphoma patient likely good match treatment method falls presence proliferative disease malignancy not responded chemotherapy minimal disease state key kwak says not success giving vaccine established tumors big tumors tumors dispersed body present overcapacity problem body create finite number antibody producing white blood cells given time period tumor cells